子公司停产三月内无法恢复触发ST，未名医药开盘一字跌停

Core Viewpoint - The suspension of production at Tianjin Weiming Biopharmaceutical Co., Ltd. has led to Shandong Weiming Pharmaceutical Co., Ltd. being placed under other risk warnings, resulting in a significant drop in stock price and market capitalization [1][2]. Group 1: Company Impact - Tianjin Weiming, a key subsidiary, accounted for 60.09% of Weiming Pharmaceutical's revenue and 9.8% of its net profit in 2024, indicating its critical role in the company's financial performance [2]. - The suspension of Tianjin Weiming's production is expected to have a substantial impact on Weiming Pharmaceutical's operations, as the subsidiary's previous issues with product quality have already affected sales and revenue [2][4]. - The company reported a revenue decline of 57.84% in Q1 2025, with a net loss of 36.85 million yuan, reflecting ongoing financial struggles exacerbated by the suspension [4]. Group 2: Regulatory and Market Context - The Tianjin Municipal Drug Administration found that Tianjin Weiming's production did not comply with the Good Manufacturing Practice (GMP) standards, leading to the suspension of its production and sales [1][2]. - Prior to the suspension, Tianjin Weiming faced scrutiny when a batch of its interferon α2b spray was flagged for not meeting biological activity standards, resulting in multiple regions halting purchases [2]. - In December 2023, Tianjin Weiming won a bid for the exclusive supply of interferon α2b spray at a price of 33.58 yuan for a specific volume, but this was later revoked in April 2025, further impacting the company's market position [3].